Appropriate Use Criteria for Nuclear Medicine in the Evaluation and Treatment of Differentiated Thyroid Cancer
- 2 March 2020
- journal article
- research article
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 61 (3) , 375-396
Abstract
No abstract availableThis publication has 120 references indexed in Scilit:
- Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome?Endocrine-Related Cancer, 2010
- Appropriate Time for Post-Therapeutic I-131 Whole Body ScanClinical Nuclear Medicine, 2009
- Incidence of radiation thyroiditis and thyroid remnant ablation success rates following 1110 MBq (30 mCi) and 3700 MBq (100 mCi) post‐surgical 131I ablation therapy for differentiated thyroid carcinomaClinical Endocrinology, 2008
- External Validation of a Measurement Tool to Assess Systematic Reviews (AMSTAR)PLOS ONE, 2007
- Radioactive Iodine Lobe Ablation as an Alternative to Completion Thyroidectomy for Follicular Carcinoma of the ThyroidThyroid®, 2002
- Resistance of [ 18 F]-Fluorodeoxyglucose-Avid Metastatic Thyroid Cancer Lesions to Treatment with High-Dose Radioactive IodineThyroid®, 2001
- The Nonimpact of Thyroid Stunning: Remnant Ablation Rates in 131I-Scanned and Nonscanned IndividualsThe Journal of Clinical Endocrinology & Metabolism, 2001
- Are Posttherapy Radioiodine Scans Informative and Do They Influence Subsequent Therapy of Patients with Differentiated Thyroid Cancer?Thyroid®, 2000
- Radioiodine and thyroid disease: the beginningSeminars in Nuclear Medicine, 1996
- Relation between Effective Radiation Dose and Outcome of Radioiodine Therapy for Thyroid CancerNew England Journal of Medicine, 1983